-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $266

Benzinga·03/03/2026 14:30:33
Listen to the news
Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $200 to $266.